Omega Therapeutics, Inc. - OMGA STOCK NEWS

Omega Therapeutics, a clinical-stage biotechnology company, announced it will present new preclinical data at three upcoming scientific meetings. The presentations will showcase the company's OMEGA platform and its ability to engineer therapeutic candidates that regulate gene expression with high specificity.

The company will present posters at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, the 12th International mRNA Health Conference, and the American Association for the Study of Liver Diseases' (AASLD) 75th Annual The Liver Meeting®. These presentations will cover topics such as epigenetic upregulation of CXCL9 and CXCL10 in hepatocellular carcinoma, multi-gene tuning of α-globin for thalassemia treatment, and upregulation of HNF4α using epigenomic controllers.

Omega Therapeutics (Nasdaq: OMGA) is developing programmable epigenomic mRNA medicines to treat or cure a broad range of diseases by modulating gene expression without altering native nucleic acid sequences.

Halda Therapeutics, a biotech company developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics for cancer, has appointed Christian Schade as President, CEO, and Board member. Schade brings over 20 years of pharma and biotech industry experience, including leadership in clinical pipeline development and value-creating deals. Tim Shannon continues as Board Chairman.

Schade's appointment comes as Halda prepares to enter clinical trials, with the first RIPTAC therapeutic expected to begin trials in the first half of 2025. The company is focusing on developing therapies for prostate and breast cancer. Schade's previous roles include CEO of Aprea Therapeutics, Growth Partner at Flagship Pioneering, and executive positions at Novira, Omthera Pharmaceuticals, and Medarex.

Omega Therapeutics (Nasdaq: OMGA) has published preclinical data for OTX-2002, their epigenomic controller targeting the MYC gene in hepatocellular carcinoma (HCC), in Nature Communications. The study demonstrates OTX-2002's ability to downregulate MYC expression and inhibit tumor growth in HCC models, both as a monotherapy and in combination with standard treatments.

Key findings include:

• Rapid reduction in MYC mRNA and protein levels
• Decreased viability of HCC cell lines
• Dose-dependent tumor size reduction
• Synergistic effects with other cancer therapies
• Beneficial impact on the tumor microenvironment

OTX-2002 is currently in a Phase 1/2 clinical trial (MYCHELANGELO™ I) for HCC and other MYC-associated solid tumors. The data supports the potential of Omega's OMEGA platform to develop programmable epigenomic mRNA medicines for various diseases.

Omega Therapeutics (Nasdaq: OMGA), a biotech company developing programmable epigenomic mRNA medicines, has appointed Jennifer Nelson, Ph.D., as Senior Vice President of Research. Dr. Nelson brings over 20 years of experience in RNA- and DNA-based therapies and platform development. She previously served as Vice President of Research at Flagship Pioneering and held key positions at Laronde and Moderna Therapeutics.

The company's CEO, Mahesh Karande, expressed confidence in Dr. Nelson's expertise to advance the OMEGA platform and pursue strategic partnerships. Dr. Nelson's appointment comes as Thomas McCauley, Ph.D., the former Chief Scientific Officer, leaves the company. Omega Therapeutics is focused on developing programmable epigenomic mRNA medicines to treat various diseases, including cancer and obesity.

Omega Therapeutics (Nasdaq: OMGA) reported Q2 2024 financial results and company progress. Key highlights include:

1. Advancing MYCHELANGELO™ I trial for OTX-2002 in hepatocellular carcinoma, with plans to select recommended dose and initiate expansion cohorts in Q4 2024.

2. Presented preclinical data at ASGCT showing durable gene expression upregulation using epigenomic controllers.

3. Appointed Kaan Certel as Chief Business Officer and elected Richard N. Kender to Board of Directors.

4. Q2 2024 financials: $45.9M cash on hand, expected to fund operations into Q1 2025. R&D expenses decreased to $12.9M from $25.0M in Q2 2023. Net loss reduced to $16.3M from $29.7M in Q2 2023.

Omega Therapeutics (Nasdaq: OMGA), a clinical-stage biotechnology company, announced the election of Richard N. Kender to its Board of Directors. With a 35-year career at Merck, Kender brings extensive experience in corporate finance, business development, and corporate licensing. He previously served as Senior Vice President at Merck. Kender's expertise is expected to be instrumental as Omega advances its platform of programmable epigenomic mRNA medicines, targeting a wide range of diseases. Omega's leadership praised Kender's strategic insights and experience in guiding biotech companies toward their business goals.

Omega Therapeutics (Nasdaq: OMGA) has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 10:40 a.m. ET. Omega Therapeutics is a clinical-stage biotech company developing programmable epigenomic mRNA medicines for various diseases. The events will be webcast live on Omega’s investor relations website, with replays available for 90 days.

Omega Therapeutics has appointed Kaan Certel, Ph.D., as Chief Business Officer. Certel brings over 20 years of biopharmaceutical and academic experience, having previously held key roles at BioCity Biopharma and Sanofi. His new responsibilities at Omega include global business development and strategic partnerships. Omega, a clinical-stage biotechnology company, focuses on developing programmable epigenomic mRNA medicines. CEO Mahesh Karande highlighted Certel's extensive expertise and leadership in business development as key assets for advancing the company's OMEGA platform and pipeline.

Omega Therapeutics presented new preclinical data at ASGCT 2024 showcasing durable and tunable gene expression upregulation using epigenomic controllers. The data exhibited a significant increase in gene expression levels for various gene types and regulatory mechanisms, with a stable increase lasting up to 55 days. The OMEGA platform also demonstrated the ability to simultaneously target multiple regulatory elements for synergistic effects. These findings highlight the potential of precision epigenomic control in addressing diseases.